Although patients treated with enzalutamide have low pretreatment GR expression levels, the percentage of GR-overexpressing cells within the tumor increases posttreatment, especially in patients who develop resistance and disease progression.[7] The latter tumors showed uneven restoration of AR-target genes (Fig. 2). This evidence concerns the gene NR3C1 and neoplasm.